This work builds on our prior studies demonstrating a marked and durable effect of dasatinb in a NSCLC patient with a KIBRAF mutation [2] and dasatinib-induced senescence that was dependent upon RAF heterodimerization in NSCLC cell lines [3]. The gene discussed is RAF1; the disease is non-small cell lung carcinoma.